References
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
- Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25: 2902–8.
- Stark Vance V. Bevacizumab (AvastinR) and CPT-11 (CamptosarR) in the treatment of relapsed malignant glioma. Neurooncol 2005;7:369 (abstract).
- Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, . Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;7:740–5.
- Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27: 4733–40.
- Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, . Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011;50:630–5.
- Sherman JH, Aregawi DG, Lai A, Fathallah-Shaykh HM, Bierman PJ, Linsky K, . Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 2009; 73:1924–6.